PTPN22 R620W gene editing in T cells enhances low avidity TCR responses

  1. Warren Anderson
  2. Fariba Barahmand-pour-Whitman
  3. Peter S Linsley
  4. Karen Cerosaletti
  5. Jane H Buckner
  6. David J Rawlings  Is a corresponding author
  1. Seattle Children's Research Institute, United States
  2. Benaroya Research Institute, United States
  3. University of Washington, United States

Abstract

A genetic variant in the gene PTPN22 (R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited (620W), non-risk edited (620R) or knock out T cells from the same donor. PTPN22 risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked PTPN22 KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to PTPN22 non-risk T cells. Together, these findings suggest that, in primary human T cells, PTPN22 rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.

Data availability

Prism files containing the numerical data and statistical tests used to generate all figures has been provided

Article and author information

Author details

  1. Warren Anderson

    Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Pittsboro, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9315-5233
  2. Fariba Barahmand-pour-Whitman

    Benaroya Research Institute, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Peter S Linsley

    Benaroya Research Institute, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8960-4307
  4. Karen Cerosaletti

    Benaroya Research Institute, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7403-6239
  5. Jane H Buckner

    Benaroya Research Institute, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. David J Rawlings

    Department of Pediatrics, University of Washington, Seattle, United States
    For correspondence
    drawling@u.washington.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0810-1776

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK111802)

  • Warren Anderson
  • Fariba Barahmand-pour-Whitman
  • Peter S Linsley
  • Karen Cerosaletti
  • Jane H Buckner
  • David J Rawlings

Seattle Children's Foundation (Children's Guild Association Endowed Chair in Pediatric Immunology)

  • David J Rawlings

Seattle Children's Research Institute (Center for Immunity and Immunotherapies)

  • David J Rawlings

Seattle Children's Research Institute (Program for Cell and Gene Therapy)

  • David J Rawlings

Seattle Children's Research Institute (Hansen Investigator in Pediatric Innovation Endowment)

  • David J Rawlings

Benaroya Family Gift Fund

  • David J Rawlings

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Study Approval (Human Subjects)For gene editing experiments using adult PBMCs, human donor leukopaks were purchased from the Fred Hutchinson Cancer Research Center, which were obtained from consenting donors under an IRB-approved protocol and cryopreserved. For gene editing experiments using umbilical cord blood derived PBMCs, cord units were purchased from the Bloodworks Northwest, which were obtained with consent under an IRB-approved protocol and cryopreserved. After collection, all samples were de-identified for the protection of human blood donors.

Copyright

© 2023, Anderson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,787
    views
  • 278
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Warren Anderson
  2. Fariba Barahmand-pour-Whitman
  3. Peter S Linsley
  4. Karen Cerosaletti
  5. Jane H Buckner
  6. David J Rawlings
(2023)
PTPN22 R620W gene editing in T cells enhances low avidity TCR responses
eLife 12:e81577.
https://doi.org/10.7554/eLife.81577

Share this article

https://doi.org/10.7554/eLife.81577

Further reading

    1. Immunology and Inflammation
    Zhiyan Wang, Nore Ojogun ... Mingfang Lu
    Research Article

    The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.